Skip to main content
Erschienen in: ästhetische dermatologie & kosmetologie 5/2019

05.10.2019 | Melasma | derma aktuell

Von Hydrochinon bis PRP

Neue Therapien der Hyperpigmentierung am Horizont?

verfasst von: Dr. Miriam Sonnet

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Goldstandard für die Behandlung von Pigmentunregelmäßigkeiten der Haut ist nach wie vor Hydrochinon. Aber auch andere Therapien, wie plättchenreiches Plasma, sind in Sicht — deren Wirksamkeit muss sich allerdings in weiteren Studien zeigen.
Literatur
2.
Zurück zum Zitat Brenner M, Berking C. Grundlagen der Hautpigmentierung. Der Hautarzt. 2010; 61: 554–60 CrossRef Brenner M, Berking C. Grundlagen der Hautpigmentierung. Der Hautarzt. 2010; 61: 554–60 CrossRef
3.
Zurück zum Zitat Bayerl C. Behandlung von Hyperpigmentierungen. ästhetische dermatologie & kosmetologie. 2015; 7: 30–35 CrossRef Bayerl C. Behandlung von Hyperpigmentierungen. ästhetische dermatologie & kosmetologie. 2015; 7: 30–35 CrossRef
5.
Zurück zum Zitat Filoni A et al. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019; 18: 458–63 CrossRef Filoni A et al. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019; 18: 458–63 CrossRef
6.
Zurück zum Zitat Kwon SH. Melasma: Updates and perspectives. Exp Dermatol. 2019; 28: 704–8 CrossRef Kwon SH. Melasma: Updates and perspectives. Exp Dermatol. 2019; 28: 704–8 CrossRef
7.
Zurück zum Zitat Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J Am Board Fam Med. 2019; 32: 628–38 CrossRef Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. J Am Board Fam Med. 2019; 32: 628–38 CrossRef
8.
Zurück zum Zitat Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3: 20–31 PubMedPubMedCentral Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3: 20–31 PubMedPubMedCentral
9.
Zurück zum Zitat Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation is there a case to be made? J Drugs Dermatol. 2015; 14: 337–41 PubMed Roberts WE. Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation is there a case to be made? J Drugs Dermatol. 2015; 14: 337–41 PubMed
10.
Zurück zum Zitat Vierkötter A et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010; 130: 2719–26 CrossRef Vierkötter A et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010; 130: 2719–26 CrossRef
11.
Zurück zum Zitat Ferreira Cestari T et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007; 6: 36–9 CrossRef Ferreira Cestari T et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007; 6: 36–9 CrossRef
12.
Zurück zum Zitat Ahmad Nasrollahi S, Sabet Nematzadeh M, Samadi A, Ayatollahi A, Yadangi S, Abels C et al. Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin. Clin Cosmet Investig Dermatol. 2019; 12: 437–44 CrossRef Ahmad Nasrollahi S, Sabet Nematzadeh M, Samadi A, Ayatollahi A, Yadangi S, Abels C et al. Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin. Clin Cosmet Investig Dermatol. 2019; 12: 437–44 CrossRef
13.
Zurück zum Zitat Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004; 74: 319–22 PubMed Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004; 74: 319–22 PubMed
14.
Zurück zum Zitat Monteiro RC et al. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013; 58: 157 CrossRef Monteiro RC et al. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013; 58: 157 CrossRef
15.
Zurück zum Zitat Deo KS et al. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013; 58: 281–5 CrossRef Deo KS et al. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013; 58: 281–5 CrossRef
16.
Zurück zum Zitat Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016; 15: 269–82 CrossRef Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016; 15: 269–82 CrossRef
17.
Zurück zum Zitat Dayal S et al. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017; 16: 35–42 CrossRef Dayal S et al. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017; 16: 35–42 CrossRef
18.
Zurück zum Zitat Kirsch B et al. Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study. J Clin Aesthet Dermatol. 2019; 12: 40–5 PubMedPubMedCentral Kirsch B et al. Evaluating the Efficacy, Safety, and Tolerability of the Combination of Tazarotene, Azelaic Acid, Tacrolimus, and Zinc Oxide for the Treatment of Melasma: A Pilot Study. J Clin Aesthet Dermatol. 2019; 12: 40–5 PubMedPubMedCentral
20.
Zurück zum Zitat Hollinger JC et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018; 11: 28–37 PubMedPubMedCentral Hollinger JC et al. Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review. J Clin Aesthet Dermatol. 2018; 11: 28–37 PubMedPubMedCentral
21.
Zurück zum Zitat Ertam I et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008; 35: 570–4 CrossRef Ertam I et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008; 35: 570–4 CrossRef
22.
Zurück zum Zitat Makino ET et al. Evaluation of a hydroquinone-free skin brightening product using in-vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013; 12: s16–s20 PubMed Makino ET et al. Evaluation of a hydroquinone-free skin brightening product using in-vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol. 2013; 12: s16–s20 PubMed
23.
Zurück zum Zitat Griffiths CE et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415–21 CrossRef Griffiths CE et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993; 129: 415–21 CrossRef
24.
Zurück zum Zitat Hegyi V, Hegyi J. Methoden und Mittel zur Pigmentierung und Depigmentierung. Der Hautarzt. 2010; 61: 586–92 CrossRef Hegyi V, Hegyi J. Methoden und Mittel zur Pigmentierung und Depigmentierung. Der Hautarzt. 2010; 61: 586–92 CrossRef
25.
Zurück zum Zitat Rivas S, Pandya AG. Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 2013; 14: 359–76 CrossRef Rivas S, Pandya AG. Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review. Am J Clin Dermatol. 2013; 14: 359–76 CrossRef
27.
Zurück zum Zitat Choi S et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002; 27: 513–5 CrossRef Choi S et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002; 27: 513–5 CrossRef
28.
Zurück zum Zitat Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. Journal of Pakistan Association of Dermatologists. 2009; 19: 158–63 Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. Journal of Pakistan Association of Dermatologists. 2009; 19: 158–63
29.
Zurück zum Zitat Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. J Am Acad Dermatol. 2015; 72: 105–7 CrossRef Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. J Am Acad Dermatol. 2015; 72: 105–7 CrossRef
30.
Zurück zum Zitat Alvin G et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011; 10: 1025–31 PubMed Alvin G et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011; 10: 1025–31 PubMed
31.
Zurück zum Zitat Castanedo-Cazares JP et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013; 6: 29–36 CrossRef Castanedo-Cazares JP et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013; 6: 29–36 CrossRef
32.
Zurück zum Zitat Janney MS et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019; 12: 63–7 PubMedPubMedCentral Janney MS et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019; 12: 63–7 PubMedPubMedCentral
33.
Zurück zum Zitat Zhu CY et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019; 29: 55–8 PubMed Zhu CY et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019; 29: 55–8 PubMed
35.
Zurück zum Zitat Padhi T, Pradhan S. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Indian J Dermatol. 2015; 60: 520 PubMedPubMedCentral Padhi T, Pradhan S. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Indian J Dermatol. 2015; 60: 520 PubMedPubMedCentral
36.
Zurück zum Zitat Wattanakrai P et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010; 36: 76–87 CrossRef Wattanakrai P et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010; 36: 76–87 CrossRef
37.
Zurück zum Zitat Imhof L et al. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016; 42: 853–7 CrossRef Imhof L et al. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016; 42: 853–7 CrossRef
38.
Zurück zum Zitat Abdel-Raouf Mohamed H et al. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019; 18: 517–23 CrossRef Abdel-Raouf Mohamed H et al. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma. J Cosmet Dermatol. 2019; 18: 517–23 CrossRef
39.
Zurück zum Zitat Merchán WH et al. Platelet-rich plasma, a powerful tool in dermatology. J Tissue Eng Regen Med. 2019; 13: 892–901 CrossRef Merchán WH et al. Platelet-rich plasma, a powerful tool in dermatology. J Tissue Eng Regen Med. 2019; 13: 892–901 CrossRef
40.
Zurück zum Zitat Hofny ERM et al. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019; 30: 396–401 CrossRef Hofny ERM et al. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019; 30: 396–401 CrossRef
41.
Zurück zum Zitat Cayırlı M et al. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014; 26: 401–2 CrossRef Cayırlı M et al. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014; 26: 401–2 CrossRef
43.
Zurück zum Zitat Arrowitz C et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139: 1691–1698.e6 CrossRef Arrowitz C et al. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139: 1691–1698.e6 CrossRef
44.
Zurück zum Zitat Sarkar R et al. Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and Melasma Quality of Life Index in melasma. J Cosmet Dermatol. 2019; 18: 1066–73 PubMed Sarkar R et al. Role of broad-spectrum sunscreen alone in the improvement of melasma area severity index (MASI) and Melasma Quality of Life Index in melasma. J Cosmet Dermatol. 2019; 18: 1066–73 PubMed
45.
Zurück zum Zitat Grimes PE et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5: 30–6 CrossRef Grimes PE et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018; 5: 30–6 CrossRef
46.
Zurück zum Zitat Jacobus Berlitz S et al. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019; 45: 642–50 CrossRef Jacobus Berlitz S et al. Azelaic acid-loaded nanoemulsion with hyaluronic acid - a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm. 2019; 45: 642–50 CrossRef
47.
Zurück zum Zitat Phacharapiyangkul N et al. Effect of Sucrier Banana Peel Extracts on Inhibition of Melanogenesis through the ERK Signaling Pathway. Int J Med Sci. 2019; 16: 602–6 CrossRef Phacharapiyangkul N et al. Effect of Sucrier Banana Peel Extracts on Inhibition of Melanogenesis through the ERK Signaling Pathway. Int J Med Sci. 2019; 16: 602–6 CrossRef
48.
Zurück zum Zitat Mansouri P et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015; 173: 209–17 CrossRef Mansouri P et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015; 173: 209–17 CrossRef
49.
Zurück zum Zitat Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015; 9: 4219–25 PubMedPubMedCentral Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Devel Ther. 2015; 9: 4219–25 PubMedPubMedCentral
52.
Zurück zum Zitat Ryu JH et al. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015; 307: 239–47 CrossRef Ryu JH et al. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015; 307: 239–47 CrossRef
Metadaten
Titel
Von Hydrochinon bis PRP
Neue Therapien der Hyperpigmentierung am Horizont?
verfasst von
Dr. Miriam Sonnet
Publikationsdatum
05.10.2019
Verlag
Springer Medizin
Erschienen in
ästhetische dermatologie & kosmetologie / Ausgabe 5/2019
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI
https://doi.org/10.1007/s12634-019-0092-x

Weitere Artikel der Ausgabe 5/2019

ästhetische dermatologie & kosmetologie 5/2019 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Dermatologie und bleiben Sie gut informiert – ganz bequem per eMail.